First National Bank of Omaha lifted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 10.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 24,199 shares of the medical instruments supplier’s stock after purchasing an additional 2,221 shares during the quarter. First National Bank of Omaha’s holdings in Becton Dickinson and were worth $5,181,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Legacy Advisors LLC grew its stake in Becton Dickinson and by 7,000.0% in the 4th quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 490 shares during the last quarter. FTB Advisors Inc. grew its stake in Becton Dickinson and by 114.2% in the 4th quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 290 shares during the last quarter. Harfst & Associates Inc. grew its stake in Becton Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 221 shares during the last quarter. Harvest Fund Management Co. Ltd grew its stake in Becton Dickinson and by 82.8% in the 2nd quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock valued at $146,000 after acquiring an additional 338 shares during the last quarter. Finally, Exane Derivatives grew its stake in Becton Dickinson and by 848.6% in the 4th quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock valued at $150,000 after acquiring an additional 628 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.
BDX has been the topic of a number of recent research reports. Royal Bank of Canada restated a “hold” rating and issued a $210.00 target price on shares of Becton Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price on the stock in a report on Tuesday, October 31st. Piper Jaffray Companies restated an “overweight” rating and issued a $260.00 target price (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday. Citigroup upgraded shares of Becton Dickinson and from a “sell” rating to a “neutral” rating in a report on Friday, January 5th. Finally, Morgan Stanley upped their target price on shares of Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $237.27.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.41 by $0.07. The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The company’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.33 EPS. equities research analysts predict that Becton Dickinson and Co will post 10.94 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be issued a dividend of $0.75 per share. The ex-dividend date is Thursday, March 8th. This represents a $3.00 annualized dividend and a dividend yield of 1.42%. Becton Dickinson and’s payout ratio is currently 229.01%.
COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and Co (BDX) Stake Boosted by First National Bank of Omaha” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://sportsperspectives.com/2018/02/09/becton-dickinson-and-co-bdx-stake-boosted-by-first-national-bank-of-omaha.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.